In vitro activity of PD127,391, a new quinolone against bacterial isolates from cancer patients.
The in vitro activity of PD127,391, a new 4-quinolone, was compared to that of ciprofloxacin against common clinical bacterial isolates from patients with cancer. PD127,391 was found to have a broad antimicrobial spectrum with excellent activity against gram-positive isolates (including multidrug-resistant organism such as Corynebacterium jeikeium, Enterococcus faecalis, Enterococcus faecium, methicillin-resistant Staphylococcus aureus and coagulase-negative Staphylococcus spp.). It was also extremely active against gram-negative bacilli including Pseudomonas aeruginosa. Against organisms such as Achromobacter xylosoxidans, Acinetobacter spp. and Xanthomonas maltophilia, which are frequently resistant to a variety of antimicrobial agents, PD127,391 exhibited good activity, inhibiting all such isolates at a concentration of 0.5 micrograms/ml. Overall, PD127,391 was far more potent than ciprofloxacin against gram-positive isolates and slightly more active against gram-negative isolates. No bacterium that we examined needed more than 2 micrograms/ml of PD127,391 for inhibition.
Rolston
K V
KV
Department of Medical Specialties, University of Texas M.D. Anderson Cancer Center, Houston.
Ho
D H
DH
LeBlanc
B
B
Bodey
G P
GP
D000890:Anti-Infective Agents / Q000494:pharmacology*; D002939:Ciprofloxacin / Q000494:pharmacology*; D024841:Fluoroquinolones; D006090:Gram-Negative Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D006094:Gram-Positive Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D008826:Microbial Sensitivity Tests; D009369:Neoplasms / Q000382:microbiology
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D002939:Ciprofloxacin; C057477:clinafloxacin